NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

The US Food and Drug Administration (FDA) is warning healthcare providers about potential hazards from interactions between implanted programmable cerebrospinal fluid (CSF) shunts and hearing implants ...

ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...

A study of an investigational interatrial shunt for treating high-risk heart failure patients with reduced and preserved ejection fraction suggests the device has a high degree of safety and efficacy, ...

A differential effect of atrial shunt device treatment on heart failure events was seen in prespecified subgroups of pulmonary artery systolic pressure at 20W of bicycle exercise, right atrial volume ...

Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be ...

Interatrial shunt therapy represents an innovative device-based approach to alleviating elevated left atrial pressure in patients with heart failure, particularly those with preserved ejection ...

Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking ...

A new study suggests that some patients with HFpEF may benefit from a novel, minimally invasive cardiac implant device called an atrial shunt. The study also offers new insight into the role exercise ...

ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented ...

Custom Safety Update image Individuals with an implantable programmable cerebrospinal fluid shunt are at risk for unintended changes to valve settings through exposure to magnetic fields present in ...